Table 3 Comorbidity, vasoactive drug use, mechanical ventilation support and prognosis of groups
From: Role of immature granulocytes in monitoring sepsis treatment
Grup 1. (N = 38) N(%) | Grup 2. (N = 49) N(%) | p value | ||
|---|---|---|---|---|
Gender | Female | 16 (42.1%) | 25 (51%) | 0.409 |
Male | 22 (57.9%) | 24 (49%) | ||
DM | 15 (39.5%) | 13 (26.5%) | 0.200 | |
HT | 23 (60.5%) | 24 (49%) | 0.284 | |
Cardiac disease | 17 (44.7%) | 13 (26.5%) | 0.076 | |
COPD | 10 (26.3%) | 10 (20.4%) | 0.516 | |
Malignancy | 2 (5.3%) | 13 (26.5%) | 0.01 | |
CKD | 6 (15.8%) | 5 (10.2%) | 0.437 | |
Neurologic disease | 16 (42.1%) | 16 (32.7%) | 0.364 | |
Vasoactive drug | 14 (36.8%) | 28 (57.1%) | 0.06 | |
MV | 23 (60.5%) | 43 (87.8%) | 0.003 | |
28. day mortality | live | 28 (73.7%) | 26 (53.1%) | 0.049 |
dead | 10 (26.3%) | 23 (46.9%) | ||
Hospital mortality | discharged | 24 (63.2%) | 17 (34.7%) | 0.008 |
dead | 14 (36.8%) | 32 (65.3%) | ||